Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast

Oncogene

Volumn 27, Issue 9, 2008, Pages 1243-1252

  Grochova, D ^a,b   Vankova, J ^a,b   Damborsky, J ^b   Ravcukova, B ^a   Smarda, J ^b   Vojtesek, B ^c   Smardova, J ^a,b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Conformation; Discriminating mutants; FASAY; p53; Temperature dependent mutants; Transactivation

Indexed keywords

AMIFOSTINE; DNA BINDING PROTEIN; PROTEIN P30;

ARTICLE; CORRELATION ANALYSIS; DRUG ACTIVATION; GENE MUTATION; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; TEMPERATURE DEPENDENCE; TEMPERATURE SENSITIVITY; TRANSACTIVATION;

AMIFOSTINE; AMINO ACID SUBSTITUTION; HUMANS; PROTEIN CONFORMATION; RADIATION-PROTECTIVE AGENTS; SACCHAROMYCES CEREVISIAE PROTEINS; TEMPERATURE; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 39749191326     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210748     Document Type: Article

References (40)

1. Acosta JC, Richard C, Delgado MD, Horita M, Rizzo MG, Fernadez-Luna JL et al. (2003). Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells. Mol Cancer Ther 2: 893-900.
2. Campomenosi P, Monti P, Aprile A, Abbondandolo A, Frebourg T, Gold B et al. (2001). p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 20: 3573-3579.
3. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. (1994). Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355.
4. Dearth LR, Qian H, Wang T, Baroni TE, Zeng J, Chen SW et al. (2007). Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis 28: 289-298.
5. Di Como CJ, Prives C. (1998). Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Oncogene 16: 2527-2539.
6. DiGiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC et al. (2002). A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol 1: 12-16.
7. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P et al. (1995). A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 92: 3963-3967.
8. Flaman JM, Rober V, Lenglet S, Moreau V, Iggo R, Frebourg T. (1998). Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assay in yeast. Oncogene 16: 1369-1372.
9. Friedlander P, Haupt Y, Prives C, Oren M. (1996). A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 16: 4961-4971.
10. Gaitonde SV, Riley JR, Qiao D, Martinez JD. (2000). Conformational phenotype of p53 is linked to nuclear translocation. Oncogene 19: 4042-4049.
11. Gannon JV, Greaves R, Iggo R, Lane DP. (1990). Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 12: 1595-1602.
12. Hansen S, Hupp TR, Lane DP. (1996). Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. J Biol Chem 271: 3917-3924.
13. Inga A, Storici F, Darden TA, Resnick MA. (2002). Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol Cell Biol 22: 8612-8625.
14. Ishioka C, Frebourg T, Yan YX, Vidal M, Friend SH, Schmidt S et al. (1993). Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet 5: 124-129.
15. Jia LQ, Osada M, Ishioka C, Gamo M, Ikawa S, Suzuki T et al. (1997). Screening the p53 status of human cell lines using a yeast functional assay. Mol Carcinog 19: 243-253.
16. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R et al. (2003). Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100: 8424-8429.
17. Lane PD, Hupp TR. (2003). Drug discovery and p53. Drug Discov Today 8: 347-355.
18. Levine AJ, Hu W, Feng Z. (2006). The p53 pathway: what questions remain to be explored? Cell Death Differ 13: 1027-1036.
19. Ludwig RL, Bates S, Vousden KH. (1996). Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 16: 4952-4960.
20. Maurici D, Monti P, Campomenosi P, North S, Frebourg T, Fronza G et al. (2001). Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. Oncogene 20: 3533-3540.
21. McLure KG, Lee PWK. (1999). P53 DNA binding can be modulated by factors that alter the conformational equilibrium. EMBO J 18: 763-770.
22. Milner J, Cook A, Sheldon H. (1987). A new anti-p53 monoclonal antibody, previously reported to be directed against the large T antigen of simian virus 40. Oncogene 1: 453-455.
23. Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P et al. (2005). Discriminating functional and nonfunctional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 207: 251-259.
24. North S, El-Ghissassi F, Pluquet O, Vergaegh G, Hainaut P. (2000). The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene 9: 1206-1214.
25. North S, Pluquet O, Maurici D, El-Ghissassi F, Hainaut P. (2002). Restoration of wild-type conformation and activity of temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. Mol Carcinog 33: 181-188.
26. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. (2002). The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19: 607-614.
27. Ory K, Legros Y, Auguin C, Soussi T. (1994). Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 13: 3496-3504.
28. Pataer A, Fanale MA, Roth JA, Swisher SG, Hunt KK. (2006). Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53. Cancer Gene Ther 13: 806-814.
29. Pavlova S, Mayer J, Koukalova H, Smardova J. (2003). High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast. Int J Oncol 23: 121-131.
30. Petitjean A, Achatz MIW, Borresen-Dale AL, Hainaut P, Olivier M. (2007). TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26: 2157-2165.
31. Resnick MA, Inga A. (2003). Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci USA 100: 9934-9939.
32. Scharer E, Iggo R. (1992). Mammalian p53 can function as a transcription factor in yeast. Nucl Acid Res 20: 1539-1545.
33. Selivanova G, Wiman KG. (2007). Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 26: 2243-2254.
34. Shiraishi K, Kato S, Han SY, Lui W, Otsuka K, Sakayori M et al. (2004). Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem 279: 348-355.
35. Smardova J, Ksicova K, Binkova H, Pavlova S, Rottenberg J, Koukalova H. (2004). Analysis of tumor suppressor p53 status in head and neck squamous cell carcinoma. Oncol Rep 11: 923-929.
36. Smardova J, Nemajerova A, Trbusek M, Vagunda V, Kovarik J. (2001). Rare somatic p53 mutation identified in breast cancer: a case report. Tumor Biol 22: 59-66.
37. Smardova J, Smarda J, Koptikova J. (2005). Functional analysis of p53 tumor suppressor in yeast. Differentiation 73: 261-277.
38. Stephen CW, Lane DP. (1992). Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. J Mol Biol 22: 577-583.
39. Xirodimas DP, Lane DP. (1999). Molecular evolution of the thermosensitive PAb1620 epitope of human p53 by DNA shuffling. J Biol Chem 274: 28042-28049.
40. Zhang W, Guo XY, Hu GY, Liu WB, Shay JW, Deisseroth AB. (1994). A temperature-sensitive mutant of human p53. EMBO J 13: 2535-2544.